Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 06804103

Next Previous
Drug Profile

PF 06804103

Alternative Names: anti-HER2 ADC; Anti-HER2 antibody-drug conjugate - Pfizer; anti-HER2-vc0101; anti-HER2-vcAur0101 ADC; Anti-NG-HER2 ADC; anti-NG-Her2-vc0101 ADC; NG-HER2 ADC; PF-06804103

Latest Information Update: 23 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 28 May 2025 Adverse events and efficacy data from a phase I trial in Solid Tumours presented at 126th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 03 Sep 2024 Pfizer terminates a phase-I trial for Solid tumours (Monotherapy) and Solid tumours (Combination therapy) in USA, Spain, South Korea, Russia, Italy, Australia (unspecified route) due to the stage in drug development and assessment of PF 06804103 relative to the leading external competition (NCT03284723)
  • 31 Aug 2021 Pfizer completes Phase-I trials for Solid tumours (Monotherapy) and Solid tumours (Combination therapy) in USA, Spain, South Korea, Russia, Italy, Australia (unspecified route) (NCT03284723)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top